Why the study?
This review was conducted to examine the current literature on diabetes-related kidney disease and optimal cardio-renal risk management following recent outcome trials and updated international guidelines.
Design
Review
Authors
Loading...
Supports RAS blockade for DKD progression; leaves open optimal integration with newer cardio-renal therapies.
SGLT2 inhibitors and renin-angiotensin system blockade are key therapies for reducing the progression of kidney disease and cardiovascular risk in patients with type 2 diabetes.
Stephens et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: